Oliger Christy J. — SEC insider filings
SEC reporting owner CIK 1822092. 31 insider filings on record with FilingPulse; latest filed 2026-09-02.
Transaction summary — filings shown
Covers all 31 filings on record, filed 2020-08-31 to 2026-09-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 46.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| REATA PHARMACEUTICALS INC (RETA) | Director | 5 | — | — | 17 |
| Karyopharm Therapeutics Inc. (KPTI) | Director | 7 | — | — | 7 |
| Nuvalent, Inc. (NUVL) | Director | 3 | — | — | 6 |
| Replimune Group, Inc. (REPL) | Director | 6 | — | — | 6 |
| Vera Therapeutics, Inc. (VERA) | Director | 3 | — | — | 3 |
| LAVA Therapeutics NV (LVTX) | Director | 2 | — | — | 2 |
| Sierra Oncology, Inc. (SRRA) | Director | 2 | — | — | 2 |
| Bicara Therapeutics Inc. (BCAX) | Director | 1 | — | — | 1 |
| RayzeBio, Inc. (RYZB) | Director | 1 | — | — | 1 |
| Zenas BioPharma, Inc. (ZBIO) | Director | 1 | — | — | 1 |
Insider filings — Oliger Christy J.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Zenas BioPharma, Inc. (ZBIO) | Grant/award (A): 37,000 (derivative) @ $0 | EDGAR |
| 2026-07-29 | 4 | Bicara Therapeutics Inc. (BCAX) | Grant/award (A): 38,950 (derivative) @ $0 | EDGAR |
| 2026-07-15 | 4 | Nuvalent, Inc. (NUVL) | Code (U): 1,324 @ $124 · Disposition to issuer (D): 6,091 · Disposition to issuer (D): 6,119 (derivative) | EDGAR |
| 2026-06-18 | 4 | Nuvalent, Inc. (NUVL) | Grant/award (A): 3,444 @ $0 | EDGAR |
| 2026-05-26 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 15,508 @ $0 | EDGAR |
| 2026-05-26 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 17,084 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2025-11-17 | 4 | LAVA Therapeutics NV (LVTX) | Disposition to issuer (D): 33,390 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Nuvalent, Inc. (NUVL) | Grant/award (A): 3,971 @ $0 · Grant/award (A): 6,119 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 4,600 (derivative) @ $0 | EDGAR |
| 2025-05-16 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 14,000 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | LAVA Therapeutics NV (LVTX) | Grant/award (A): 33,390 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | Vera Therapeutics, Inc. (VERA) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-05-30 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 69,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2024-02-27 | 4 | RayzeBio, Inc. (RYZB) | Disposition to issuer (D): 114,579 (derivative) | EDGAR |
| 2023-09-26 | 4 | REATA PHARMACEUTICALS INC (RETA) | Disposition to issuer (D): 5,565 · Disposition to issuer (D): 1,250 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 106 (derivative) · Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 180 (derivative) · +2 more | EDGAR |
| 2023-06-09 | 4 | REATA PHARMACEUTICALS INC (RETA) | Grant/award (A): 1,682 @ $93.61 · Grant/award (A): 2,137 (derivative) @ $0 | EDGAR |
| 2023-05-25 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2023-04-04 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 25,200 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Sierra Oncology, Inc. (SRRA) | Disposition to issuer (D): 18,000 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | REATA PHARMACEUTICALS INC (RETA) | Grant/award (A): 3,883 @ $34.76 · Grant/award (A): 5,620 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 23,900 (derivative) @ $0 | EDGAR |
| 2022-04-05 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2021-12-03 | 4 | Replimune Group, Inc. (REPL) | Grant/award (A): 33,000 (derivative) @ $0 | EDGAR |
| 2021-06-14 | 4 | REATA PHARMACEUTICALS INC (RETA) | Grant/award (A): 5,000 (derivative) @ $0 · Grant/award (A): 180 (derivative) @ $83.24 | EDGAR |
| 2021-06-04 | 4 | Sierra Oncology, Inc. (SRRA) | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2021-05-21 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 23,900 (derivative) @ $0 | EDGAR |
| 2021-04-16 | 4 | REATA PHARMACEUTICALS INC (RETA) | Grant/award (A): 1,250 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0 · Grant/award (A): 106 (derivative) @ $52.85 | EDGAR |
| 2020-08-31 | 4 | Karyopharm Therapeutics Inc. (KPTI) | Grant/award (A): 32,800 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-26 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1822092 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs